Abstract
In this issue of CMAJ Valiyeva and colleagues[1][1] report on the impact of 3 regulatory warnings on prescription rates of antipsychotic drugs among elderly adults with dementia. Their finding — that the warnings did not achieve the desired outcome — is similar to that in a recent study on the